EICHORPublic-registry site landscape for NCT05265273, “A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis”, a Myasthenia Gravis study sponsored by Janssen Research & Development, LLC. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT05265273 (registry record) |
| Study title | A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis |
| Official title | An Open-Label Uncontrolled Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Activity of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis |
| Sponsor | Janssen Research & Development, LLC |
| Condition(s) | Myasthenia Gravis |
| Phase | PHASE2 / PHASE3 |
| Listed sites | 19 |
| Site countries | United States, Japan, Netherlands, Poland |
Patient-friendly overview of this study: eichor.com/study/NCT05265273.
Eichor generates a preliminary site-risk snapshot for NCT05265273 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Myasthenia Gravis trials
More from Janssen Research & Development, LLC
← Eichor home · All tracked trials · Myasthenia Gravis studies · Weekly briefs
